Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
New investors in 2023 must understand the current market landscape. Familiarize yourself with essential tips and strategies to thrive in investing.
28,353 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Choosing between VNQ and RWO isn’t just about geography. This guide breaks down how US-focused VNQ compares to global...
Oil ETFs have soared 100% plus this year, underscoring a powerful rebound in crude. This report breaks down what’s dr...
As we enter June, investors wonder if summer headwinds are already priced into stocks. This article breaks down prici...
Jim Cramer advises investors to wait before buying Vertiv after a pronounced dip, arguing that selling pressure could...
Gold has surged roughly 50% in the past year, but most portfolios remain lightly exposed. State Street’s 2026 outlook...
VUG, Vanguard’s Growth ETF, with about $223B in assets, is outperforming many active large-cap funds while charging j...
NVIDIA earnings arrive with high volatility and big questions. This article breaks down the historical post-earnings ...
ServiceNow's stock is down this year, but CEO Bill McDermott argues AI will accelerate growth, not derail it, outlini...
A single-session drop in the 3X leveraged FNGU ETN trimmed a $10,000 bet to $8,392, illustrating how tech leverage ca...
As Omnicom wraps up the 2025 fiscal year, investors want clarity on growth, margins, and capital allocation. This gui...
Looking ahead to 2026, investors want a clear view of how Global Partners will navigate energy markets, margins, and ...